Family History and Relapse in Pediatric Acute Myeloid Leukemia.

Autor: Mehrvar A; Mahak's Pediatric Cancer Treatment and Research Center, Army Medical Science University, Tehran, Iran., Tashvighi M; Mahak's Pediatric Cancer Treatment and Research Center, Islamic Azad University of Qom, Qom, Iran., Faranoush M; Mahak's Pediatric Cancer Treatment and Research Center, Iran University of Medical Sciences, Tehran, Iran., Reinhardt D; University Children's Hospital Essen, AML-BFM Study Group, Essen, Germany., Niktoreh Mofrad N; Mahak's Pediatric Cancer Treatment and Research Center, Tehran, Iran., Hedayati Asl AA; Mahak's Pediatric Cancer Treatment and Research Center, Tehran, Iran., Alebouyeh M; Mahak's Pediatric Cancer Treatment and Research Center, Tehran, Iran.
Jazyk: angličtina
Zdroj: Pediatric blood & cancer [Pediatr Blood Cancer] 2015 Dec; Vol. 62 (12), pp. 2235-7. Date of Electronic Publication: 2015 Jul 16.
DOI: 10.1002/pbc.25649
Abstrakt: We report the epidemiology and characteristics of acute myeloid leukemia and outcomes of its treatment with the AML-BFM 83 protocol at the Mahak Pediatric Cancer Treatment and Research Center, Tehran, Iran, from 2007 to 2012. A positive family history of cancer or leukemia was associated with the risk of relapse (family history of cancer in relapse: n = 11; 61%, P = 0.136, leukemia: n = 7; 39%; P = 0.016). Treatment-related mortality was 19% and associated with underweight patients (n = 5; 62.5%; P = 0.158). Event-free and overall survivals were 36% (SE = 3.5) and 44% (SE = 3.4), respectively. These data suggest a possible relationship between family history and relapse rate.
(© 2015 Wiley Periodicals, Inc.)
Databáze: MEDLINE
Externí odkaz: